UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia

Pharmacology & therapeutics (Oxford), 2008-12, Vol.120 (3), p.317-332

2008

Volltextzugriff (PDF)

Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)

The Journal of pharmacology and experimental therapeutics, 2008-07, Vol.326 (1), p.209-217

2008

Volltextzugriff (PDF)

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

Neuropharmacology, 2012-03, Vol.62 (3), p.1473-1483

2012

Volltextzugriff (PDF)

A chemogenetic approach for dopamine imaging with tunable sensitivity

Nature communications, 2024-07, Vol.15 (1), p.5551-22, Article 5551

2024

Volltextzugriff (PDF)

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Neuropharmacology, 2006-05, Vol.50 (6), p.755-760

2006

Volltextzugriff (PDF)

Glutamatergic regulation of brain histamine neurons: In vivo microdialysis and electrophysiology studies in the rat

Neuropharmacology, 2015-12, Vol.99, p.1-8

2015

Volltextzugriff (PDF)

Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial

Movement disorders, 2022-03, Vol.37 (3), p.513-524

2022

Volltextzugriff (PDF)

Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior

The Journal of pharmacology and experimental therapeutics, 2005-07, Vol.314 (1), p.310-319

2005

Volltextzugriff (PDF)

The dopamine D1 receptor positive allosteric modulator, DETQ, improves cognition and social interaction in aged mice and enhances cortical and hippocampal acetylcholine efflux

Behavioural brain research, 2024-02, Vol.459, p.114766-114766, Article 114766

2024

Volltextzugriff (PDF)

The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice

Behavioural brain research, 2019-04, Vol.361, p.139-150

2019

Volltextzugriff (PDF)

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat

The Journal of pharmacology and experimental therapeutics, 2006-08, Vol.318 (2), p.810

2006

Volltextzugriff (PDF)

In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268)

The Journal of pharmacology and experimental therapeutics, 2009-12, Vol.331 (3), p.1126

2009

Volltextzugriff (PDF)

Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge

Neuropharmacology, 2010-03, Vol.58 (3), p.632-639

2010

Volltextzugriff (PDF)

The Dopamine D1 Receptor Positive Allosteric Modulator Mevidalen (LY3154207) Enhances Wakefulness in the Humanized D1 Mouse and in Sleep-Deprived Healthy Male Volunteers

The Journal of pharmacology and experimental therapeutics, 2022-03, Vol.380 (3), p.143-152

2022

Volltextzugriff (PDF)

Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor

Molecular pharmacology, 2023-03, Vol.103 (3), p.176-187

2023

Volltextzugriff (PDF)

Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: A microdialysis study

Journal of neuroscience research, 2012-03, Vol.90 (3), p.588-596

2012

Volltextzugriff (PDF)

Ensemble Docking Approach to Mitigate Pregnane X Receptor-Mediated CYP3A4 Induction Risk

Journal of chemical information and modeling, 2023-01, Vol.63 (1), p.173-186

2023

Volltextzugriff (PDF)

Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs

Nature chemical biology, 2020-03, Vol.16 (3), p.240-249

2020

Volltextzugriff (PDF)

Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primate

Psychopharmacology, 2023-05, Vol.240 (5), p.1033-1048

2023

Volltextzugriff (PDF)

Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders

Advances in pharmacology (1990), 2019, Vol.86, p.273-305

2019

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects

Clinical pharmacology in drug development, 2021-04, Vol.10 (4), p.393-403

2021

Volltextzugriff (PDF)

Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor

Molecular pharmacology, 2018-10, Vol.94 (4), p.1232-1245

2018

Volltextzugriff (PDF)

Synthesis and Pharmacological Characterization of 2‑(2,6-Dichlorophenyl)-1-((1S,3R)‑5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)‑yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor

Journal of medicinal chemistry, 2019-10, Vol.62 (19), p.8711-8732

2019

Volltextzugriff (PDF)

1 – 25 von 303

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(284)
Mit Volltextzugriff
(242)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia

Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

A chemogenetic approach for dopamine imaging with tunable sensitivity

Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Glutamatergic regulation of brain histamine neurons: In vivo microdialysis and electrophysiology studies in the rat

Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial

Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior

The dopamine D1 receptor positive allosteric modulator, DETQ, improves cognition and social interaction in aged mice and enhances cortical and hippocampal acetylcholine efflux

Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas

The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat

In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268)

Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge

The Dopamine D1 Receptor Positive Allosteric Modulator Mevidalen (LY3154207) Enhances Wakefulness in the Humanized D1 Mouse and in Sleep-Deprived Healthy Male Volunteers

Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor

Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: A microdialysis study

Ensemble Docking Approach to Mitigate Pregnane X Receptor-Mediated CYP3A4 Induction Risk

Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs

Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primate

Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects

Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor

Suchergebnisse filtern